Two is better than one: Benefits of VEGF and PDGF inhibition in ovarian cancer

Cancer Biology and Therapy

Volumn 9, Issue 3, 2010, Pages 183-185

  Sennino, Barbara ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AX102; Bevacizumab; Blood vessels; Epithelial ovarian cancer; PDGF; Pericytes; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; AX 102; BEVACIZUMAB; DOCETAXEL; IMATINIB; PLATELET DERIVED GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; MICROVASCULATURE; NONHUMAN; NOTE; OVARY CANCER; PERICYTE; TUMOR GROWTH; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APTAMERS, NUCLEOTIDE; COMBINED MODALITY THERAPY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PERICYTES; PROTO-ONCOGENE PROTEINS C-SIS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 77953565644     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.3.11117     Document Type: Note

References (26)

1. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009; 9:167-81.
2. Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 2005; 8:169-82.
3. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-27.
4. Duyndam MC, Hilhorst MC, Schluper HM, Verheul HM, van Diest PJ, Kraal G, et al. Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol 2002; 160:537-48. (Pubitemid 34160331)
5. Collinson FJ, Hall GD, Perren TJ, Jayson GC. Development of antiangiogenic agents for ovarian cancer. Expert Rev Anticancer Ther 2008; 8:21-32.
6. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-57.
7. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. Exs 2005:209-31.
8. Betsholtz C, Lindblom P, Gerhardt H. Role of pericytes in vascular morphogenesis. Exs 2005; 115-25.
9. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003; 314:15-23.
10. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15:102-11. (Pubitemid 40127638)
11. Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001; 153:543-53. (Pubitemid 34280141)
12. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277:242-5. (Pubitemid 27446080)
13. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002; 160:985-1000. (Pubitemid 34224587)
14. Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, et al. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol 2008; 198:477.
15. Apte SM, Fan D, Killion JJ, Fidler IJ. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 2004; 10:897-908.
16. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111:1287-95.
17. Sennino B, Falcon BL, McCauley D, Le T, McCauley T, Kurz JC, et al. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 2007; 67:7358-67. (Pubitemid 47206566)
18. von Tell D, Armulik A, Betsholtz C. Pericytes and vascular stability. Exp Cell Res 2006; 312:623-9.
19. Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005; 23:973-81.
20. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004; 4:806-13. (Pubitemid 39331152)
21. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62.
22. Heuchel R, Berg A, Tallquist M, Ahlen K, Reed RK, Rubin K, et al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling. Proc Natl Acad Sci USA 1999; 96:11410-5. (Pubitemid 29487394)
23. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61:2929-34. (Pubitemid 32691937)
24. Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin CH, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003; 9:3779-87. (Pubitemid 37169248)
25. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:5165-71.
26. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26:76-82.